FILE PHOTO: A vial of some of the first 500,000 of the 2-million AstraZeneca coronavirus disease (COVID-19) vaccine doses that Canada has secured through a deal with the Serum Institute of India in partnership with Verity Pharma at a facility in Milton, Ontario, Canada March 3, 2021. REUTERS/Carlos Osorio?/File Photo
(Reuters) - Canada's health department on Wednesday continues to back AstraZeneca Plc's COVID-19 vaccine even as it updated its label to provide information on rare blood clots associated with a low platelet count following an immunization shot.
Health Canada said it has not received any reports of these blood clots to date.
